Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of CCR2 in the Development of Streptozotocin-Treated Diabetic Cardiomyopathy
Xin Tan, Lizhi Hu, Zhiping Shu, et al.
Diabetes (2019) Vol. 68, Iss. 11, pp. 2063-2073
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Cardiac fibrosis
Nikolaos G. Frangogiannis
Cardiovascular Research (2020) Vol. 117, Iss. 6, pp. 1450-1488
Open Access | Times Cited: 717
Basic Mechanisms of Diabetic Heart Disease
Rebecca H. Ritchie, E. Dale Abel
Circulation Research (2020) Vol. 126, Iss. 11, pp. 1501-1525
Open Access | Times Cited: 469
Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure
Anis Hanna, Nikolaos G. Frangogiannis
Cardiovascular Drugs and Therapy (2020) Vol. 34, Iss. 6, pp. 849-863
Open Access | Times Cited: 295
Distinct Types of Cell Death and the Implication in Diabetic Cardiomyopathy
Yun Chen, Yuyun Hua, Xinshuai Li, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 169
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms
Teresa Salvatore, Pia Clara Pafundi, Raffaele Galiero, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 107
Irisin attenuates type 1 diabetic cardiomyopathy by anti-ferroptosis via SIRT1-mediated deacetylation of p53
Yuan-juan Tang, Zhen Zhang, Yan Tong, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 28
Inflammation in diabetes complications: molecular mechanisms and therapeutic interventions
Lu Zhao, Haoran Hu, Lin Zhang, et al.
MedComm (2024) Vol. 5, Iss. 4
Open Access | Times Cited: 21
Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities
Izabela Tuleta, Nikolaos G. Frangogiannis
Advanced Drug Delivery Reviews (2021) Vol. 176, pp. 113904-113904
Open Access | Times Cited: 87
Preliminary evidence for the presence of multiple forms of cell death in diabetes cardiomyopathy
Jinjing Wei, Yongting Zhao, Haihai Liang, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 1, pp. 1-17
Open Access | Times Cited: 69
Therapeutic siCCR2 Loaded by Tetrahedral Framework DNA Nanorobotics in Therapy for Intracranial Hemorrhage
Wei Fu, Lu Ma, Yan Ju, et al.
Advanced Functional Materials (2021) Vol. 31, Iss. 33
Closed Access | Times Cited: 64
Inhibition of CCR2 attenuates neuroinflammation and neuronal apoptosis after subarachnoid hemorrhage through the PI3K/Akt pathway
Qi Tian, Yujia Guo, Feng Shi, et al.
Journal of Neuroinflammation (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 56
USP28 Serves as a Key Suppressor of Mitochondrial Morphofunctional Defects and Cardiac Dysfunction in the Diabetic Heart
Saiyang Xie, Shi‐qiang Liu, Tong Zhang, et al.
Circulation (2023) Vol. 149, Iss. 9, pp. 684-706
Closed Access | Times Cited: 38
Mechanisms and Therapeutic Prospects of Diabetic Cardiomyopathy Through the Inflammatory Response
Namrita Kaur, Yingshu Guan, Rida Raja, et al.
Frontiers in Physiology (2021) Vol. 12
Open Access | Times Cited: 48
Роль циркулирующих биомаркеров у пациентов, перенесших COVID-19
О. А. Осипова, R. N. Shepel, Ольга Анатольевна Каруцкая, et al.
Актуальные проблемы медицины (2023) Vol. 46, Iss. 3, pp. 231-244
Open Access | Times Cited: 20
LncRNA ZNF593-AS alleviates diabetic cardiomyopathy via suppressing IRF3 signaling pathway
Rong Xie, Jiahui Fan, Jianpei Wen, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 32, pp. 689-703
Open Access | Times Cited: 16
The role and therapeutic potential of macrophages in the pathogenesis of diabetic cardiomyopathy
Shan Zhang, Xueying Zhu, Yupeng Chen, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Chemokines in cardiac fibrosis
Ruoshui Li, Nikolaos G. Frangogiannis
Current Opinion in Physiology (2020) Vol. 19, pp. 80-91
Open Access | Times Cited: 36
SIRT6: A potential therapeutic target for diabetic cardiomyopathy
Tao Wu, Yiwei Qu, Shengjie Xu, et al.
The FASEB Journal (2023) Vol. 37, Iss. 8
Open Access | Times Cited: 12
Immune cell dynamics in heart failure: implicated mechanisms and therapeutic targets
Gen Li, Wu He, Daowen Wang
ESC Heart Failure (2025)
Open Access
Heart Rate Variability, Microvascular Dysfunction, and Inflammation: Exploring the Potential of taVNS in Managing Heart Failure in Type 2 Diabetes Mellitus
Serge C. Thal, Sergey Shityakov, Ellaine Salvador, et al.
Biomolecules (2025) Vol. 15, Iss. 4, pp. 499-499
Open Access
FTZ Ameliorates Diabetic Cardiomyopathy by Inhibiting Inflammation and Cardiac Fibrosis in the Streptozotocin-Induced Model
Lexun Wang, Huijuan Wu, Yanyue Deng, et al.
Evidence-based Complementary and Alternative Medicine (2021) Vol. 2021, pp. 1-16
Open Access | Times Cited: 25
Targeting Mediators of Inflammation in Heart Failure: A Short Synthesis of Experimental and Clinical Results
Timea Magdolna Szabo, Attila Frigy, E Nagy
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 13053-13053
Open Access | Times Cited: 24
Hyperglycemia amplifies TLR-mediated inflammatory response of M(IL4) macrophages to dyslipidemic ligands
Luis Ernesto Badillo-Garcia, Quan Liu, Kim Ziebner, et al.
Journal of Leukocyte Biology (2024) Vol. 116, Iss. 1, pp. 197-204
Open Access | Times Cited: 3
The cytoplasmic sensor, the AIM2 inflammasome: A precise therapeutic target in vascular and metabolic diseases
Jiuguo Lin, Jiaojiao Wang, Jian Fang, et al.
British Journal of Pharmacology (2024) Vol. 181, Iss. 12, pp. 1695-1719
Closed Access | Times Cited: 3
CCR2 and PTPRC are regulators of tumor microenvironment and potential prognostic biomarkers of lung adenocarcinoma
Jie Wei, Dalang Fang, Weijie Zhou
Annals of Translational Medicine (2021) Vol. 9, Iss. 18, pp. 1419-1419
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top